Regeneron Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
REGN Regeneron Pharmaceuticals Inc
IIPR Innovative Industrial Properties Inc
NVCN Neovasc Inc
CDE Coeur Mining Inc
BRID Bridgford Foods Corp
SOR Source Capital Inc
RCLFW Rosecliff Acquisition Equity I Warrants Exp 11 Feb 2026 *W EXP 02/11/2026
FAST Fastenal Co
UKOMW Ucommune International Equity Warrant Exp 17th Nov 2025 *W EXP 11/17/2025
KMI Kinder Morgan Inc
Go

Health Care : Biotechnology | Large Cap Blend
Company profile

Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. It also provides Expresse service assurance and CloudCheck WiFi experience management solutions.

Postmarket

Last Trade
Delayed
$594.90
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$594.90
Day's Change
-1.66 (-0.28%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
601.88
Day's Low
588.92
Volume
(Below Average)
Volume:
545,365

10-day average volume:
606,305
545,365

Display:

Providers:

UpdateCancel
6 providers
Today's News, July 06, 2022
Regeneron to Report Second Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2022

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2022 financial and operating results on Wednesday, August 3, 2022, before the U.S. financial markets open. The Company will host a conference call...(PR Newswire)

July 01, 2022
Regeneron Completes Purchase of Sanofi's Stake in Libtayo(R) (cemiplimab)

Company provides anticipated impact to second quarter 2022 financial results due to recently completed business development transactions Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has completed the acquisition of Sanofi's...(PR Newswire)

June 29, 2022
EYLEA(R) (aflibercept) Injection sBLA for Every 16-week Dosing Regimen in Patients with Diabetic Retinopathy Accepted for FDA Review

If approved, extended regimen would provide a longer treatment interval and additional dosing flexibility, alongside approved every 4- and 8-week dosing regimens Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug...(PR Newswire)

June 24, 2022
Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose

Serum TTR reductions were sustained at all doses tested with follow-up now reaching 12 months in the 0.1 and 0.3 mg/kg and six months in the 0.7 and 1.0 mg/kg cohorts Pharmacokinetic modeling and simulation indicated that an 80 mg fixed dose...(PR Newswire)

Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose

EQNX::TICKER_START (NasdaqGM:NTLA),(NASDAQ:REGN), EQNX::TICKER_END -- Serum TTR reductions were sustained at all doses tested with follow-up now reaching 12 months in the 0.1 and 0.3 mg/kg and six months in the 0.7 and 1.0 mg/kg cohorts (Globe Newswire)

June 07, 2022
FDA Approves Dupixent(R) (dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis

Children treated with Dupixent and topical corticosteroids (TCS) achieved clearer skin, experienced significantly improved overall disease severity and significantly reduced itch compared to TCS alone at week 16 in a Phase 3 trial (PR Newswire)

June 02, 2022
Kuros Biosciences: Completion of the Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals Triggers a $5 Million Milestone Payment

EQNX::TICKER_START (SWX:KURN.SW),(NASDAQ:REGN),(NasdaqGM:CMPI),(NasdaqGM:XOMA), EQNX::TICKER_END Ad-hoc announcement pursuant to Article 53 of the SIX listing rules ? $2.5 million of milestone to be paid to XOMA Corporation under royalty agreement (Globe Newswire)

May 31, 2022
Regeneron Completes Acquisition of Checkmate Pharmaceuticals

Acquisition strengthens Regeneron's innovative portfolio of immuno-oncology candidates and diversified approach to cancer treatment Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has successfully acquired Checkmate...(PR Newswire)

FDA Accepts Dupixent(R) (dupilumab) for Priority Review in Adults with Prurigo Nodularis

Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has...(PR Newswire)

May 21, 2022
Evkeeza(R) (evinacumab) Phase 3 Trial Demonstrates 48% LDL-C Reduction in Children with Ultra-rare Form of High Cholesterol

Children already on other lipid-lowering therapies entered the trial with dangerously high LDL-C (264 mg/dL on average), and 79% saw their LDL-C reduced by at least half at 24 weeks FDA submission planned by end of 2022 (PR Newswire)

May 20, 2022
FDA Approves Dupixent(R) (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic Esophagitis

Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more than two months ahead of FDA's Priority Review action date Dupixent 300 mg weekly significantly improved signs and...(PR Newswire)

May 17, 2022
Vyriad, Inc. Raises $29.5M in Series B Funding Led by Renowned Genetics Entrepreneur

Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced $29.5M in new funding led by Mr. Harry Stine of Stine Seed Farms, Inc. with participation from existing...(PR Newswire)

Vyriad, Inc. Raises $29.5M in Series B Funding Led by Renowned Genetics Entrepreneur

Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced $29.5M in new funding led by Mr. Harry Stine of Stine Seed Farms, Inc. with participation from existing...(PR Newswire)

May 02, 2022
Regeneron Announces Investor Conference Presentations

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: -- BofA Securities Healthcare Conference at 1:20 p.m. PT (4:20 p.m. ET) on Tuesday, May 10, 2022 -- Goldman Sachs 43rd Annual Global Healthcare...(PR Newswire)

April 20, 2022
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Checkmate Pharmaceuticals, Inc. Buyout

Wilmington, Delaware--(Newsfile Corp. - April 20, 2022) - Rigrodsky Law, P.A. is investigating Checkmate Pharmaceuticals, Inc. ("Checkmate") (NASDAQ: CMPI) regarding possible breaches of fiduciary duties and other violations of law related to...(Newsfile)

April 19, 2022
SHAREHOLDER ALERT: Weiss Law Investigates Checkmate Pharmaceuticals, Inc.

Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Checkmate Pharmaceuticals, Inc. ("Checkmate" or the "Company") (NASDAQ: CMPI), in connection with the proposed acquisition of the...(PR Newswire)

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: American Campus Communities, Inc. (NYSE - ACC), Checkmate Pharmaceuticals, Inc. (Nasdaq - CMPI), Natus Medical Incorporated (Nasdaq - NTUS), Flexible Solutions International Inc. (NYSE - FSI)

Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There...(Globe Newswire)

CHECKMATE PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of CMPI and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) breached their fiduciary duties or violated...(Globe Newswire)

Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types

Proposed ~$250 million all-cash acquisition strengthens Regeneron's portfolio of diverse and combinable immuno-oncology candidates Lead investigational asset vidutolimod is a potential best-in-class TLR9 agonist, with demonstrated clinical responses...(PR Newswire)

Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types

Proposed ~$250 million all-cash acquisition strengthens Regeneron's portfolio of diverse and combinable immuno-oncology candidates Lead investigational asset vidutolimod is a potential best-in-class TLR9 agonist, with demonstrated clinical...(Globe Newswire)

Next >

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.